Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation | Zendy

Shirley Qiong Yan | Zendy; Brian Seyboth | Zendy; Rachel Kobos | Zendy; Anne Eaton | Zendy; Susan K. Seo | Zendy; Nina Cohen | Zendy

Open Access

Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation

Author(s) -

Shirley Qiong Yan,

Brian Seyboth,

Rachel Kobos,

Anne Eaton,

Susan K. Seo,

Nina Cohen

Publication year - 2017

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/pix022

Subject(s) - voriconazole , medicine , dosing , hematopoietic stem cell transplantation , cohort , trough level , adverse effect , transplantation , trough concentration , pediatric cancer , pharmacokinetics , population , therapeutic drug monitoring , pediatrics , cancer , tacrolimus , dermatology , antifungal , environmental health

There are limited pediatric population pharmacokinetic data for voriconazole dosing, particularly in younger children. In a cohort of 34 patients younger than 3 years receiving voriconazole, the majority (n = 23, 68%) had a low initial serum concentration <1 mg/L. Among 23 children <2 years old, 19 (83%) had an initial trough <1 mg/L. There was large intra- and interindividual variability in trough levels. Dosing also varied from 3.3 to 19.6 mg/kg per dose. Only 2 of 34 patients had a documented adverse drug reaction attributable to voriconazole. More data are needed to establish optimal dosing in very young children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research